2024
An Interventional Radiologist's Guide to Lung Cancer
Fish A, Madoff D. An Interventional Radiologist's Guide to Lung Cancer. Seminars In Interventional Radiology 2024, 41: 121-128. PMID: 38993601, PMCID: PMC11236454, DOI: 10.1055/s-0044-1786725.Peer-Reviewed Original ResearchLung cancer patientsLung cancerTissue diagnosisInterventional radiologistsCancer patientsField of interventional oncologyTreating lung cancer patientsTreatment of lung cancerEarly-stage diseaseAdvanced medical therapiesLung cancer complicationsBiopsy complicationsRadiation therapyPercutaneous ablationSurgical therapyMedical therapyInterventional oncologyEndovascular therapyInvasive treatmentCancer complicationsCancer deathTherapyGold standardCancerTreatment pathways
2023
Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments
Iezzi R, Gangi A, Posa A, Pua U, Liang P, Santos E, Kurup A, Tanzilli A, Tenore L, De Leoni D, Filippiadis D, Giuliante F, Valentini V, Gasbarrini A, Goldberg S, Meijerink M, Manfredi R, Kelekis A, Colosimo C, Madoff D. Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments. Cancers 2023, 15: 308. PMID: 36612304, PMCID: PMC9818393, DOI: 10.3390/cancers15010308.Peer-Reviewed Original ResearchInterventional oncologyLocoregional treatmentCancer patientsNew locoregional treatmentMultiple body systemsLow-risk alternativeImage-guided techniquesLocoregional proceduresSurgical therapyPalliative careInvasive proceduresPotential cureDisease sitesNew indicationsTreatment of diseasesInnovative indicationsOncologyPatientsTreatmentEvidence-reported literatureExpert discussionIndicationsWide spectrumReviewWidespread use
2017
Incorporating Quality of Life Metrics in Interventional Oncology Practice
Li D, Madoff DC. Incorporating Quality of Life Metrics in Interventional Oncology Practice. Seminars In Interventional Radiology 2017, 34: 313-321. PMID: 29249854, PMCID: PMC5730443, DOI: 10.1055/s-0037-1608826.Peer-Reviewed Original ResearchCancer patientsPatients' qualityInterventional radiologistsBrief Pain InventoryVisual analog scaleNumerical rating scaleQuality of lifePalliative intentCancer QualityPain InventoryAnalog scaleLife QuestionnaireOncology practiceLife instrumentsOutcome measuresLife measuresInvasive proceduresFunctional assessmentLife metricsPatientsEuropean OrganizationRating ScaleCancer therapyRadiologistsCommon instruments
2016
The role of interventional oncology in the palliative care of cancer patients
Li D, Hussaini S, Kang J, Madoff D. The role of interventional oncology in the palliative care of cancer patients. Expert Review Of Quality Of Life In Cancer Care 2016, 1: 73-87. DOI: 10.1080/23809000.2016.1142358.Peer-Reviewed Original ResearchInterventional oncologistsCancer patientsPain controlFluid drainageInterventional oncologyClinical practice highlightPeritoneovenous shunt placementPleural catheter placementTrans-arterial embolizationCeliac neurolysisDecompressive gastrostomyBowel obstructionSymptomatic reliefPalliative optionShunt placementCatheter placementPalliative careComplex comorbiditiesInvasive optionUncontrolled hemorrhageImage-guided proceduresPatientsOncologistsRelative efficacyCommon procedure
2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albumin